Association of ECE1 gene polymorphisms and essential hypertension risk in the Northern Han Chinese: A case–control study

Hao Wang | Jielin Liu | Kuo Liu | Ya Liu | Jie Wen | Zuoguang Wang | Shaojun Wen

Abstract

**Background:** The ECE1 gene polymorphisms have been studied as a candidate gene in essential hypertension, but no consensus has been reached. To systematically explore their possible association, a case–control study was conducted.

**Methods:** This study included 398 hypertensive subjects and 596 healthy volunteers as control subjects in the Northern Han Chinese. A total of 10 tag SNPs of ECE1 gene were genotyped successfully by TaqMan assay.

**Results:** A total of 10 SNPs (rs212544, rs2076280, rs115071, rs2076283, rs9426748, rs11590928, rs212515, rs2236847, rs2282715, and rs2774028) were identified as the tag SNPs for ECE1 gene. Although no positive connection has been found in general population, several SNPs have been found to be related to EH risk in gender-stratified subgroup analysis. In males, rs115071 T allele influenced EH risk in a protective manner, with dominant model (TT+TC vs. CC: \( p = .032, \) OR = 0.655, 95% CI = 0.445–0.965), additive model (TT vs. TC vs. CC: \( p = .019, \) OR = 0.616, 95% CI = 0.411–0.924), as well as allele comparison (T vs. C: \( p = .045, \) OR = 0.702, 95% CI = 0.496–0.992). While, in females, rs212544 AA genotype would increase the onset risk of EH (recessive model: AA vs. GA+GG, \( p = .024, \) OR = 1.847, 95% CI = 1.086–3.142). In the three haplotype blocks identified, rs2076283-rs2236847 C-T haplotype was associated with a decreased risk of EH (OR = 0.558, \( p = .046 \)).

**Conclusion:** The current case–control study suggested that several SNPs and related haplotypes on ECE1 gene might be associated with the susceptibility of EH in certain gender subgroups in the Northern Han Chinese population.

**KEYWORDS**
endothelin converting enzyme-1, essential hypertension, polymorphism, sex difference, the Northern Han Chinese population
1 | INTRODUCTION

Essential hypertension (EH) is a worldwide public health problem, which contributes greatly to the global burden of cardiovascular morbidity and mortality (Mills et al., 2016). In China, hypertension is one of the fastest escalating diseases of the past 30 years (Gao et al., 2013). According to a recent survey published on Circulation, the prevalence of hypertension was approximately 27.9% in the Chinese population over 18 years in 2012 to 2015, leading to a high prevalence of heart failure, stroke, arterial fibrillation, and multiple target organs injuries (Wang et al., 2018). EH is generally regarded as a complex disorder which results from the interplay of genetic and environmental factors. Evidences from pedigree study have suggested that the correlation between high blood pressure phenotypes is significantly stronger between parents and offspring than that between spouses, suggesting that the exploration for hypertension-susceptibility genetic factors are also crucial for the prevention to EH besides environmental factors (Stamler, Stamler, Riedlinger, Algera, & Roberts, 1979).

Endothelin (ET) is the most potent vasoconstrictor and vasopressor up to now. It plays an important role in the occurrence and development of hypertension (Dhaun & Webb, 2019). Endothelin converting enzyme-1 (ECE1), the key enzyme in ET system, can produce active endothelin (ET) by hydrolysis of the big endothelin (big-ET) (Luscher & Barton, 2000). Previous studies found that some of the single-nucleotide variants of ECE1 can influence the mRNA level of ECE1, then affect the activity of this enzyme and finally induce changes in the expression level of ET (Minamino et al., 1997; Shirai et al., 2006; Turner & Murphy, 1996).

Single-nucleotide polymorphism (SNP) is one of the most common genetic variants in humans, and is a key factor in disease susceptibility and drug response. As far as the authors know, there are five studies studying the relationship between ECE1 SNPs and EH risk or blood pressure levels in healthy population (Banno et al., 2007; Funalot et al., 2004; Funke-Kaiser et al., 2003; Iemitsu et al., 2006; Li et al., 2017). These studies mainly focused on three SNPs, including rs213045 (c.-338C>A), rs213046 (c.-839T>G) as well as rs212528 (c.-338C>A), rs213046 (c.-839T>G) as well as rs212528 (c.616-329A>G). Rs213045 and rs213046 locate in promoter region of ECE1 gene. Funalot found that female, elderly rs213045 AA carriers tended to have higher SBP, heart rate and average blood pressure than CA and CC genotype carriers (p-value = 0.01, .02, and .006) (Funalot et al., 2004). Funke reported the same results after studying in female un-treated EH patients. Meanwhile, his study also reported the association between rs213046 and the blood pressure level, which said that rs213046 G allele carriers have higher level of diurnal and nocturnal blood pressure (Funke-Kaiser et al., 2003). A case–control study conducted in Northern Han Chinese found that rs213045 A allele is associated with increased risk of EH (OR = 1.447, p = .014), however, it failed to find the relationship between rs213046 and EH risk (Li et al., 2017). Another SNP, rs212528 is in the 17th intron in ECE1 gene. A case–control study from Japanese population found that the EH risk of female rs212528 AA carriers increased by 0.4 folds, compared with AG and GG genotypes (Banno et al., 2007). However, AA carriers were reported to have lower level of SBP, DBP, and heart rate in another healthy Japanese population (Iemitsu et al., 2006).

It is easy to see that previous studies made great contributions, as they provided us a clue that ECE1 SNPs might be associated with EH or some other blood pressure-related diseases. However, considering the existing studies were conducted in different populations, some in healthy participants and some in EH patients, and in different ethnics, which might be with different genetic background and influenced by different environmental factors, and most importantly they achieved inconsistent results, further studies are still in badly need. Therefore, we conducted a case–control study to explore the association between the SNP loci of ECE1 gene and EH in Northern Han Chinese.

2 | MATERIALS AND METHODS

2.1 | Ethics statement

The current study complies with the Declaration of Helsinki. Written informed consent was obtained from all participants. The aim, design, and detailed protocol of this study were approved by the local ethics committee of Beijing Anzhen Hospital of the Capital University of Medical Sciences.

2.2 | Study design and subjects

This is a case–control study. All participants were unrelated Northern Han Chinese origin and over 18 years old. Participants in control group were recruited from the physical examination center of Anzhen Hospital affiliated to Capital University of Medical Sciences (Beijing, China) and another two examination centers at the local health stations: Liulijiiao and Guozhuang in the suburbs of Beijing. Patients in EH group were screened at hypertension clinic of Anzhen Hospital. Blood pressure was measured by trained and certified observers according to a common protocol adapted from procedures recommended by European Society of Hypertension (Mancia et al., 2013). After sitting for 30 min in a quiet room, three measurements with a standardized mercury sphygmomanometer were performed with at least 5 min intervals. One of the four bladders (standard, larger, smaller, and pediatric) was chosen and all readings were obtained from the right arm. SBP and DBP were defined...
according to Korotkoff I and V. Heart rate was measured by cardiac auscultation. Hypertension was defined as the average SBP ≥140 mmHg and/or the average DBP ≥90 mmHg and/or self-reported current treatment for hypertension with antihypertensive medication. The control subjects had systolic pressure <140 mmHg and diastolic pressures <90 mmHg, respectively, and should never been diagnosed as hypertension or treated for hypertension (Mancia et al., 2013). Patients meet any of the following criteria are excluded in this study: (a) secondary hypertension, including pheochromocytoma, aldosteronism, hyperthyroidism, renal vascular disease, nephrotic syndrome, and so on; (b) white coat hypertension; (c) diabetes mellitus; (d) serious cardiovascular and cerebrovascular diseases; (e) multiple organ failure or malignant tumor, the estimated life expectancy is less than 1 year. Physical examination, a questionnaire and serum biochemical profile were administered to each of the participants. Information on smoking and drinking habits was obtained by interview. Smoker was defined as the cigarette consumer who has smoked ≥100 cigarettes, and drinker was defined as the alcohol consumer who drank ≥12 times during the year (Ge et al., 2005; Gu et al., 2006).

2.3 | SNP identification

The tag SNP approach was used in the current study to predict the remaining common SNPs. It was conducted as follows. Firstly, the ECE1 common SNPs (minor allele frequency [MAF] >10%) were searched from the Han Chinese data sets of the International HapMap Project SNP database (http://www.hapmap.org/, HapMap Genome Browser release #27). Then, the tag SNPs with an $r^2 \geq 0.85$ examined by Haplovieview 4.2 software (http://www.broad.mit.edu/mpg/haploview) were selected.

2.4 | SNP genotyping

Blood was taken into ethylene-diamine tetra-acetic (EDTA)-containing receptacles. Genomic DNA was extracted from peripheral blood according to standard phenol-chloroform methods. SNPs were genotyped using the TaqMan assay. The ECE1 SNP Taqman probes and primers which were labeled with different fluorescent dyes were obtained from Applied Biosystems Assay-by-Design Service for SNP genotyping (Applied Biosystems, Foster City, CA, USA). The sample DNA was amplified by PCR following the recommendations of the manufacturer. Thermal cycling was done on a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) with the following conditions: initial denaturation and activation at 95°C for 10 min, followed by 35 cycles of 95°C for 20s, and 62°C for 1 min. Genotypes were differentiated by analyzing the fluorescence levels of PCR products using an ABI PRISM 7900HT Sequence Detector (Applied Biosystems). Genotyping was performed blindly to all other data.

2.5 | Sample power calculation

The statistical power of this study was calculated by using Quanto software (version 1.2.4, University of Southern California). Dominant genetic model was adopted and statistical significance was set at $p < .05$. Given the available sample size, a statistical power of over 93% was achieved for detecting a risk allele with an OR of 1.5.

2.6 | Statistical analysis

The SPSS software (version 22.0; IBM SPSS Statistics) was used for statistical analysis. Continuous variables were expressed as mean ± standard deviation. Categorical variables were shown as frequency (percentage). The independent-samples t test and Pearson’s $\chi^2$ test were used for comparisons between groups. The presence of Hardy–Weinberg equilibrium was detected by the $\chi^2$ test for goodness of fit based on a web program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Genotypic and allelic frequencies were compared between hypertensive group and control group. Binominal logistic regression was used to examine the association between ECE1 SNPs and the risk for hypertension under different models of inheritance (additive, dominant, and recessive and homozygote comparison) after adjusting for the confounding factors. Construction of the linkage disequilibrium (LD) map and haplotype blocks within ECE1 SNPs was based on genotypes and utilized Haploview software (version 4.2; http://www.broad.mit.edu/mpg/haploview/). Taking into account the covariates, haplotype-based logistic regressive analysis was conducted with PLINK software (version 2.0, http://pngu.mgh.harvard.edu/~purcell/plink/). Haplotypes with frequencies of less than 1% were ignored in the current study. All analysis used a two-tailed estimation of significance. The statistical significance was defined as $p < .05$.

3 | RESULTS

3.1 | Characteristics of the study population

Altogether 398 hypertension patients (236 males and 162 females; mean age 51.33 ± 6.88 years) and 596 healthy controls (334 males and 262 females; mean age 51.00 ± 8.71 years) were included in this study. The subjects were adequately matched for age and gender between groups. As shown in
TABLE 1  Clinical characteristic of the study population

|                | Overall                      | Hypertension (n = 398) | Normotension (n = 596) | p   |
|----------------|------------------------------|------------------------|------------------------|-----|
| Gender (Male)  | Male                         | Hypertension (n = 236) | Normotension (n = 334) | p   |
|                | Male                         | Hypertension (n = 162) | Normotension (n = 262) | p   |
| Age (years)    | 51.33 ± 6.88                | 50.32 ± 6.58           | 50.43 ± 7.95           | .855|
|                | 51.00 ± 8.71                | 51.72 ± 9.57           | .183                   |
| SBP (mmHg)^a   | 135.40 ± 17.23              | 135.01 ± 16.99         | 118.17 ± 10.78         | <.001*|
|                | 87.33 ± 13.07               | 88.97 ± 12.67          | 76.54 ± 8.12           | <.001*|
| DBP (mmHg)^a   | 90.10 ± 9.30                | 67.79 ± 8.67           | 68.54 ± 9.67           | .351|
| BMI (Kg/m²)    | 25.01 ± 7.20                | 25.99 ± 6.80           | 24.00 ± 7.00           | .001*|
| TCHO (mmol/L)  | 4.98 ± 1.75                 | 4.91 ± 0.99            | 5.17 ± 0.96            | .001*|
| HDL-C (mmol/L) | 1.14 ± 0.50                 | 1.08 ± 0.26            | 1.17 ± 0.36            | .002*|
| LDL-C (mmol/L) | 3.01 ± 0.86                 | 3.03 ± 0.86            | 3.31 ± 0.86            | <.001*|
| TG (mmol/L)    | 1.95 ± 1.61                 | 2.11 ± 1.77            | 1.69 ± 1.01            | .001*|
| Glu (mmol/L)   | 5.38 ± 0.84                 | 5.42 ± 0.82            | 5.27 ± 0.54            | .01  |
| Hcy (μmol/L)   | 9.58 ± 7.94                 | 10.44 ± 9.14           | 7.46 ± 8.85            | <.001*|
| Cr (μmol/L)    | 73.05 ± 17.23               | 80.96 ± 15.14          | 80.02 ± 10.32          | .408|
| Smokers (n, %) | 126 (31.7)                  | 119 (30.4)             | 157 (47.0)             | .421|
| Drinkers (n, %)| 173 (43.5)                  | 156 (66.1)             | 231 (69.2)             | .441|

Abbreviations: BMI, body mass index; Cr, creatinine; DBP, diastolic blood pressure; Glu, glucose; Hcy, homocysteine; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TCHO, total cholesterol; TG, triglyceride.

^aThe well-treated patients were also included in Hypertension group.

*p < .05.
Table 1, the levels of SBP, DBP, BMI, TG, glucose, and Hcy were relatively higher in hypertension group. Levels of HDL-C and LDL-C were found to be lower in hypertension group, compared with controls. The similar trend was also observed in subgroups stratified by gender. The level of TCHO was lower in the total and male hypertensive patients. No significant differences were found in the following parameters between EH patients and controls in both total and gender-stratified subgroups: age, HR, Cr, as well as incidences of smokers and drinkers.

3.2 Identification and distribution of ECE1 SNPs

According to the criteria mentioned in methods, 11 tag SNPs (rs604346, rs212544, rs2076280, rs115071, rs2076283, rs9426748, rs11590928, rs212515, rs2236847, rs2282715, and rs2774028) of the ECE1 gene were selected. All these SNPs are introns on chromosome 1. Rs604346 located at chr1:21256512, which is too close to rs115071 (chr1:21256510). During genotyping, we failed to design corresponding probe for it. So we excluded this loci during final SNP genotyping owing to technology limitations. The genotyping call rates for the rest 10 SNPs were all over 90%.

Distributions of genotype and allele frequencies in total and gender subgroups are shown in Table 2. All SNPs were in agreement with Hardy–Weinberg equilibrium for healthy controls. In present study, no statistically significant difference was found in the genotype and allele counts between hypertension group and controls in both overall population and male subgroup. However, the genotype distribution trend of rs2076280 was different between hypertensive and normotensive ones in females. The genotype frequencies of CC, CT, and TT of rs2076280 in female hypertension patients were 66.5%, 32.9%, and 0.6%, and in control group, they were 71.6%, 24.5%, and 3.9%, respectively (p = .034).

Distributions of genotype and allele frequencies in total and control group, they were 71.6%, 24.5%, and 3.9%, respectively (p = .034).

3.3 Single SNP association analysis

Binominal logistic regression analysis was performed after adjusting for confounding risk variables, including gender, age, BMI, TCHO, HDL-C, LDL-C, TG, glucose, and Hcy, with the summary of results listed in Table 3. No positive association between the 10 ECE1 SNPs and EH risk could be found in any genetic models.

However, in the further analysis stratified by gender, it was found that rs115071 was significantly associated with EH risk in males under both dominant model (TT+TC vs. CC: p = .032, OR = 0.655, 95% CI = 0.445–0.965) and additive model (TT vs. TC vs. CC: p = .019, OR = 0.616, 95% CI = 0.411–0.924), as well as also in allele comparison (T vs. C: p = .045, OR = 0.702, 95% CI = 0.496–0.992), which suggested that male T allele carriers of rs115071 have lower risk for EH. In females, rs212544 was found to be associated with EH under recessive model (AA vs. GA+GG: p = .024, OR = 1.847, 95% CI = 1.086–3.142), which indicated that female AA carriers might be more susceptible to EH. Although significant association was also observed between rs2236847 and EH in females under additive model (CC vs. CT vs. TT: p = .033, OR = 1.841, 95% CI = 1.052–3.222), no positive result was found in other genetic models for this SNP.

For the other SNPs including rs604346, rs2076280, rs2076283, rs9426748, rs11590928, rs212515, rs2282715, and rs2774028, no significant result has been found.

3.4 Haplotype association analysis

As Figure 1 revealed, three LD blocks (rs11590928-rs9426748, rs212515-rs2282715, and rs2076283-rs2236847) were identified using the standard definition of D′ and r². After adjustment for the confounding factors including gender, age, TG, TCHO, HDL-C, LDL-C, glucose, and Hcy with the PLINK software, we found that the haplotype C-T (rs2076283-rs2236847) carriers have lower risk for EH (OR = 0.558, p = .046) (Table 4).

4 DISCUSSION

In the present population, we conducted a case–control study on the association between the ECE1 polymorphisms and the susceptibility of individuals to EH. A total of 11 SNPs were identified as the tag SNPs for ECE1 gene. Although no positive connection has been found in general population, several SNPs have been found to be related to EH risk in gender-stratified subgroup analysis. In males, rs115071 T allele influenced EH risk in a protective manner. While, in females rs212544 AA genotype would increase the onset risk of EH. In the three haplotype blocks, rs2076283-rs2236847 C-T haplotype was associated with decreased risk of EH.

Previous studies also found the possible relationship between ECE1 SNPs and EH risk, but as no common SNP has been included in current study and them, we could not make further comparison. But, based on the following reasons, the authors believe that the results obtained in the current paper are rational. First, compared with earlier studies, the sample size of the present study was relatively larger. It maintained adequate statistical power, at the same time, evaded the possibility of overfitting in multivariate regression. Second, as the Han Chinese population was considered be intricately substructured, corresponding roughly to Northern Han, Central Han, and Southern Han, based on the populations of the geographical origins (Wen et al., 2004; Xu et al., 2009),
### TABLE 2  Distribution of allelic and genotypic frequencies of ECE1 SNPs and HWE information

| Genotype (frequency, %) | p | Allele (frequency, %) | p | HWEχ²  | p |
|-------------------------|---|-----------------------|---|--------|---|
| rs9426748               |   |                       |   |        |   |
| Overall                 |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 142 (39.9)              |   | 165 (46.3)            |   | 49 (13.8) |   |
| 240 (41.6)              |   | 260 (45.1)            |   | 77 (13.3) | .876 |
| Control                 |   |                       |   |        |   |
| 263 (36.9)              |   | 449 (63.1)            |   | —      | —  |
| 414 (35.9)              |   | 740 (64.1)            |   | .643   | .246 |
| Male                    |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 83 (38.8)               |   | 100 (46.7)            |   | 31 (14.5) |   |
| 138 (42.9)              |   | 145 (45)              |   | 39 (12.1) | .562 |
| Control                 |   |                       |   |        |   |
| 162 (37.9)              |   | 266 (62.1)            |   | —      | —  |
| 223 (34.6)              |   | 421 (65.4)            |   | .281   | .923 |
| Female                  |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 59 (41.5)               |   | 65 (45.8)             |   | 18 (12.7) |   |
| 102 (40)                |   | 115 (45.1)            |   | 38 (14.9) | .825 |
| Control                 |   |                       |   |        |   |
| 101 (35.6)              |   | 183 (64.4)            |   | —      | —  |
| 191 (37.5)              |   | 319 (62.5)            |   | .597   | .55  |
| rs2774028               |   |                       |   |        |   |
| Overall                 |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 218 (55.1)              |   | 147 (37.1)            |   | 31 (7.8) |   |
| 321 (54.6)              |   | 231 (39.3)            |   | 36 (6.1) | .52  |
| Control                 |   |                       |   |        |   |
| 209 (26.4)              |   | 583 (73.6)            |   | —      | —  |
| 303 (25.8)              |   | 873 (74.2)            |   | .757   | .13  |
| Male                    |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 126 (53.4)              |   | 90 (38.1)             |   | 20 (8.5) |   |
| 179 (53.9)              |   | 138 (41.6)            |   | 15 (4.5) | .141 |
| Control                 |   |                       |   |        |   |
| 130 (27.5)              |   | 342 (72.5)            |   | —      | —  |
| 168 (25.3)              |   | 496 (74.7)            |   | .397   | .069 |
| Female                  |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 92 (57.5)               |   | 57 (35.6)             |   | 11 (6.9) |   |
| 142 (55.5)              |   | 93 (36.3)             |   | 21 (8.2) | .856 |
| Control                 |   |                       |   |        |   |
| 79 (24.7)               |   | 241 (75.3)            |   | —      | —  |
| 135 (26.4)              |   | 377 (73.6)            |   | .59    | .03  |
| rs212515                |   |                       |   |        |   |
| Overall                 |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 178 (44.9)              |   | 170 (42.9)            |   | 48 (12.1) |   |
| 264 (44.8)              |   | 262 (44.5)            |   | 63 (10.7) | .757 |
| Control                 |   |                       |   |        |   |
| 266 (33.6)              |   | 526 (66.4)            |   | —      | —  |
| 388 (32.9)              |   | 790 (67.1)            |   | .764   | .028 |
| Male                    |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 109 (46.2)              |   | 102 (43.2)            |   | 25 (10.6) |   |
| 138 (41.6)              |   | 163 (49.1)            |   | 31 (9.3) | .383 |
| Control                 |   |                       |   |        |   |
| 152 (32.2)              |   | 320 (67.8)            |   | —      | —  |
| 225 (33.9)              |   | 439 (66.1)            |   | .553   | .081 |
| Female                  |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 69 (43.1)               |   | 68 (42.5)             |   | 23 (14.4) |   |
| 126 (49)                |   | 99 (38.5)             |   | 32 (12.5) | .496 |
| Control                 |   |                       |   |        |   |
| 114 (35.6)              |   | 206 (64.4)            |   | —      | —  |
| 163 (31.7)              |   | 351 (68.3)            |   | .243   | .076 |
| rs2076283               |   |                       |   |        |   |
| Overall                 |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 110 (29.3)              |   | 190 (5.5)             |   | 76 (20.2) |   |
| 162 (28)                |   | 293 (5.6)             |   | 124 (21.4) | .866 |
| Control                 |   |                       |   |        |   |
| 342 (45.5)              |   | 410 (54.5)            |   | —      | —  |
| 541 (46.7)              |   | 617 (53.3)            |   | .595   | .157 |
| Male                    |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 65 (29.1)               |   | 110 (49.3)            |   | 48 (21.5) |   |
| 83 (25.6)               |   | 169 (52.2)            |   | 72 (22.2) | .655 |
| Control                 |   |                       |   |        |   |
| 206 (46.2)              |   | 240 (53.8)            |   | —      | —  |
| 313 (48.3)              |   | 335 (51.7)            |   | .491   | .424 |
| Female                  |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 45 (29.4)               |   | 80 (52.3)             |   | 28 (18.3) |   |
| 79 (31)                 |   | 124 (48.6)            |   | 52 (20.4) | .761 |
| Control                 |   |                       |   |        |   |
| 136 (44.4)              |   | 170 (55.6)            |   | —      | —  |
| 228 (44.7)              |   | 282 (55.3)            |   | .942   | .069 |
| rs2236847               |   |                       |   |        |   |
| Overall                 |   |                       |   |        |   |
| Case                    |   |                       |   |        |   |
| 81 (20.7)               |   | 214 (54.6)            |   | 97 (24.7) |   |
| 149 (25.4)              |   | 303 (51.6)            |   | 135 (23) | .232 |
| Control                 |   |                       |   |        |   |
| 408 (52)                |   | 376 (48)              |   | —      | —  |
| 573 (48.8)              |   | 601 (51.2)            |   | .161   | .425 |
| (Continues)
| Genotype (frequency, %) | Allele (frequency, %) | HWE | χ² | p |
|------------------------|-----------------------|------|-----|---|
| **Male**               |                       |      |     |   |
| Case                   | 50 (21.4) 124 (53) 60 (25.6) — | 244 (52.1) 224 (47.9) — |      |   |
| Control                | 87 (26.3) 174 (52.6) 70 (21.1) .276 | 314 (47.4) 348 (52.6) .119 | 0.97 | .325 |
| Female                 |                       |      |     |   |
| Case                   | 31 (19.6) 90 (57) 37 (23.4) — | 164 (51.9) 152 (48.1) — |      |   |
| Control                | 62 (24.2) 129 (5.4) 65 (25.4) .392 | 259 (50.6) 253 (49.4) .714 | 0.016 | .899 |
| rs115071               | CC CT TT T C          |      |     |   |
| Overall                | 238 (65.7) 108 (29.8) 16 (4.4) — | 140 (19.3) 584 (80.7) — |      |   |
| Male                   | 149 (69.3) 56 (26) 10 (4.7) — | 76 (17.7) 354 (82.3) — |      |   |
| Female                 | 89 (60.5) 52 (35.4) 6 (4.1) — | 64 (21.8) 230 (78.2) — |      |   |
| rs212544               | GG GA AA A G          |      |     |   |
| Overall                | 123 (31.4) 182 (46.4) 87 (22.2) — | 356 (45.4) 428 (54.6) — |      |   |
| Male                   | 188 (32) 303 (51.5) 97 (16.5) .07 | 497 (42.3) 679 (57.7) .169 | 1.838 | .175 |
| Female                 | 73 (31.2) 113 (48.3) 48 (20.5) — | 209 (44.7) 259 (55.3) — |      |   |
| rs11590928             | CC CT TT T C          |      |     |   |
| Overall                | 212 (54.1) 154 (39.3) 26 (6.6) — | 206 (26.3) 578 (73.7) — |      |   |
| Male                   | 124 (53) 96 (41) 14 (6) — | 124 (26.5) 344 (73.5) — |      |   |
| Female                 | 88 (55.7) 58 (36.7) 12 (7.6) — | 82 (25.9) 234 (74.1) — |      |   |
| rs2076280              | CC CT TT T C          |      |     |   |
| Overall                | 273 (69.6) 115 (29.3) 4 (1.0) — | 125 (15.9) 659 (84.1) — |      |   |
| Male                   | 168 (71.8) 63 (26.9) 3 (1.3) — | 69 (14.7) 399 (85.3) — |      |   |
| Control                | 228 (68.9) 96 (29) 7 (2.1) .633 | 110 (16.6) 552 (83.4) .396 | 0.72 | .396 |

(Continues)
we confined our study population in Northern Han Chinese, to minimize both the racial differences and the influences induced by factors such as environmental factors, economic level, geographical location, climate, eating habits, and lifestyle. In addition, though all the 10 tag SNPs identified by Haplotype software were in the intron region of ECE1 gene, it is not surprising, as most tag SNPs detected are in intron fragment for the considerable proportion of introns on gene (Sakharkar, Chow, & Kangueane, 2004). Introns could not be translated into amino acid directly, but they play critical roles in the regulation of gene expression (Jo & Choi, 2015; Le Hir, Nott, & Moore, 2003). Besides, most tag SNPs are in close linkage disequilibrium with other functional polymorphisms (Dong et al., 2017; Grossi et al., 2018). For this purpose, we made a further confirmation by using the Haploreg v4 (http://pubs.broadinstitute.org/mammals/haploreg/haploreg_v4.php) to predict the potential function of the two positive polymorphisms, rs115071 and rs212544 (Ward, & Kellis, 2012). The results showed that there were 3 and 12 SNPs, respectively, being in linkage disequilibrium (LD) with the two SNPs mentioned above ($r^2 \geq .8$). These 15 SNPs were associated with promoter and enhancer histone marks, DNase, proteins bound, motifs changed (e.g., TATA-binding protein, NF-κB, E2F, Pou2f2, and so on) and selected eQTL hits, many of which were proved to be involved with blood pressure regulation (Lazar et al., 2006; Li et al., 2019; Prisco et al., 2014). Besides of inner authenticity, all the participants included in current study are unrelated, and all candidate SNPs satisfied HWE, so the results also have good external objective reality within certain scale.

The gender-specific associations found here are similar to the findings of previous studies (Banno et al., 2007; Funalot et al., 2004; Funke-Kaiser et al., 2003; Song, Ma, Wang, Chen, & Zhong, 2019). In clinic, Tostes found that the level of ET-1 in male patients with hypertension was significantly higher than that in females (Tostes et al., 2008). This difference also existed in animals (Intapad, Ojeda, Varney, Royals, & Alexander, 2015). Some scholars tried to make explanations from the perspective of sex hormone. For example, Polderman found that male hormones could increase the level of plasma ET expression, while estrogen would reduce the level of plasma ET. And he believed that sex hormones might change the regulatory activity of ET on kidney water and salt metabolism (Polderman et al., 1993). Other studies have shown that, because ECE1 is expressed not only in endothelial cells, but also in steroid-producing cells in the corpus luteum of the female ovary, the expression level of ECE1 would be affected by the menstrual cycle (Dubey, Jackson, Keller, Imthurn, & Rosselli, 2001; Levy et al., 2001; Webb, Ghatei, McNeill, & Collins, 2000). All of these factors may counteract or enhance the role of gene mutation. But reasons above did not account for the whole problem, because in Funalot’s study, all subjects were postmenopausal women, and only 11.5% of the population received hormone replacement therapy (Funalot et al., 2004). Therefore, this issue still needs to be further explored in the future (Gohar & Pollock, 2018).

Although we tried our best to give consideration to both inner authenticity and the representativeness of the sampling population, however, for financial constraints, there were still some limitations in current study. First is the potential for population groups. It is inevitable that participants in control group might develop EH later in life.

Table 2

| Gender | Genotype (frequency, %) | p | Allele (frequency, %) | p | HWE | $\chi^2$ | p |
|--------|------------------------|---|-----------------------|---|------|---------|---|
|        |                        |   |                       |   |      |         |   |
| Female |                        |   |                       |   |      |         |   |
| Case   | 105 (66.5)             |   | 52 (32.9)             |   | 1 (0.6) | .034*   |   |
| Control| 184 (71.6)             |   | 63 (24.5)             |   | 10 (3.9) | .555 | 2.309 | .129 |
| Overall| 109 (27.8)             |   | 191 (48.7)            |   | 92 (23.5) | .741 | 375 (47.8) | 409 (52.2) |         | .201 |
| Male   | 61 (26.1)              |   | 112 (47.9)            |   | 61 (26.1) | .259 | 234 (50) | 234 (50) |         | .669 |
| Female | 48 (30.4)              |   | 79 (50)               |   | 31 (19.6) | .402 | 141 (44.6) | 175 (55.4) |         | .158 |
| Control| 75 (29.2)              |   | 117 (45.5)            |   | 65 (25.3) | .995 | 247 (48.1) | 267 (51.9) |         | .120 |

*p < .05.
| SNP     | Models      | Genotype      | Overall OR (95% CI) | p  | Male OR (95% CI) | p  | Female OR (95% CI) | p  |
|---------|-------------|---------------|---------------------|----|-----------------|----|-------------------|----|
| rs9426748 | Additive    | AA vs. CA vs. CC | 1.063 (0.786–1.437) | .691 | 1.116 (0.754–1.652) | .584 | 0.942 (0.585–1.519) | .807 |
|         | Dominant    | CA+AA vs. CC  | 1.071 (0.806–1.422) | .637 | 1.165 (0.805–1.685) | .419 | 0.906 (0.578–1.420) | .666 |
|         | Recessive   | AA vs. CA+CC  | 1.050 (0.702–1.571) | .813 | 1.253 (0.739–2.124) | .402 | 0.824 (0.435–1.562) | .553 |
|         | Allele      | A vs. C       | 1.137 (0.916–1.412) | .245 | 1.206 (0.912–1.595) | .189 | 0.999 (0.704–1.417) | .995 |
| rs2774028 | Additive    | TT vs. CT vs. CC | 0.923 (0.692–1.230) | .584 | 0.921 (0.637–1.333) | .663 | 0.958 (0.606–1.515) | .855 |
|         | Dominant    | CT+TT vs. CC  | 0.963 (0.732–1.267) | .789 | 0.995 (0.697–1.420) | .978 | 0.930 (0.603–1.435) | .743 |
|         | Recessive   | TT vs. CT+CC  | 1.292 (0.754–2.213) | .352 | 1.874 (0.887–3.959) | .1  | 0.813 (0.360–1.836) | .618 |
|         | Allele      | T vs. C       | 0.977 (0.774–1.234) | .847 | 0.997 (0.739–1.346) | .986 | 0.949 (0.653–1.378) | .783 |
| rs212515 | Additive    | CC vs. CA vs. AA | 0.967 (0.723–1.293) | .82  | 0.825 (0.569–1.196) | .309 | 1.208 (0.760–1.920) | .424 |
|         | Dominant    | CA+CC vs. AA  | 1.020 (0.775–1.342) | .889 | 0.875 (0.614–1.429) | .463 | 1.234 (0.803–1.898) | .338 |
|         | Recessive   | CC vs. CA+AA  | 1.283 (0.835–1.973) | .256 | 1.305 (0.716–2.376) | .385 | 1.206 (0.645–2.255) | .558 |
|         | Allele      | C vs. A       | 1.074 (0.864–1.334) | .521 | 1.016 (0.767–1.347) | .911 | 1.144 (0.809–1.618) | .446 |
| rs2076283 | Additive    | GG vs. CG vs. CC | 0.974 (0.702–1.352) | .875 | 0.833 (0.542–1.280) | .404 | 1.221 (0.726–2.055) | .452 |
|         | Dominant    | CG+GG vs. CC  | 0.952 (0.698–1.298) | .755 | 0.847 (0.565–1.270) | .422 | 1.124 (0.686–1.844) | .642 |
|         | Recessive   | GG vs. CG+CC  | 0.923 (0.655–1.301) | .648 | 1.005 (0.651–1.552) | .982 | 0.790 (0.442–1.414) | .428 |
|         | Allele      | G vs. C       | 1.011 (0.821–1.246) | .915 | 0.986 (0.754–1.289) | .918 | 1.061 (0.752–1.498) | .735 |
| rs2236847 | Additive    | CC vs. CT vs. TT | 1.361 (0.965–1.920) | .079 | 1.177 (0.759–1.824) | .467 | 1.841 (1.052–3.222) | .033* |
|         | Dominant    | CT+CC vs. TT  | 1.370 (0.986–1.902) | .06  | 1.256 (0.827–1.907) | .284 | 1.681 (0.984–2.872) | .057 |
|         | Recessive   | CC vs. CT+TT  | 1.119 (0.812–1.543) | .492 | 1.308 (0.861–1.986) | .208 | 0.844 (0.508–1.403) | .514 |
|         | Allele      | C vs. T       | 1.116 (0.910–1.370) | .292 | 1.139 (0.875–1.481) | .333 | 1.062 (0.763–1.476) | .722 |
| rs115071 | Additive    | TT vs. CT vs. CC | 0.766 (0.565–1.040) | .088 | 0.616 (0.411–0.924) | .019* | 1.060 (0.663–1.693) | .809 |
|         | Dominant    | CT+TT vs. CC  | 0.790 (0.590–1.060) | .116 | 0.655 (0.445–0.965) | .032* | 1.067 (0.678–1.680) | .778 |
|         | Recessive   | TT vs. CT+CC  | 1.142 (0.571–2.283) | .707 | 1.175 (0.485–2.848) | .721 | 1.115 (0.363–3.422) | .849 |
|         | Allele      | T vs. C       | 0.817 (0.628–1.062) | .13  | 0.702 (0.496–0.992) | .045* | 1.050 (0.697–1.582) | .814 |

(Continues)
| SNP   | Models               | Genotype           | Overall       |          | Male          |          | Female       |          |
|-------|----------------------|--------------------|---------------|----------|---------------|----------|--------------|----------|
|       | OR (95% CI)<sup>a</sup> | p<sup>a</sup>  | OR (95% CI)<sup>b</sup> | p<sup>b</sup> | OR (95% CI)<sup>c</sup> | p<sup>c</sup> |
| rs212544 | Additive models | AA vs. GA vs. GG | 0.984 (0.721–1.343) | 0.919 | 1.012 (0.675–1.517) | 0.954 | 0.924 (0.568–1.504) | 0.751 |
|       | Dominant model       | GA+AA vs. GG       | 1.063 (0.792–1.427) | 0.685 | 1.026 (0.699–1.504) | 0.896 | 1.107 (0.700–1.750) | 0.665 |
|       | Recessive model      | AA vs. GA+GG       | 1.335 (0.942–1.892) | 0.105 | 1.060 (0.662–1.696) | 0.809 | 1.847 (1.086–3.142) | 0.024* |
|       | Allele comparison    | A vs. G            | 1.121 (0.912–1.378) | 0.277 | 0.996 (0.763–1.301) | 0.978 | 1.353 (0.975–1.877) | 0.071 |
| rs11590928 | Additive models | TT vs. CT vs. CC | 1.159 (0.867–1.548) | 0.319 | 1.399 (0.964–2.029) | 0.077 | 0.947 (0.595–1.507) | 0.82 |
|       | Dominant model       | CT+TT vs. CC       | 1.135 (0.862–1.494) | 0.368 | 1.357 (0.950–1.938) | 0.093 | 0.932 (0.604–1.438) | 0.75 |
|       | Recessive model      | TT vs. CT+CC       | 0.948 (0.554–1.622) | 0.844 | 0.978 (0.464–2.061) | 0.953 | 0.898 (0.412–1.959) | 0.787 |
|       | Allele comparison    | T vs. C            | 1.114 (0.882–1.408) | 0.365 | 1.211 (0.897–1.637) | 0.212 | 0.997 (0.685–1.451) | 0.986 |
| rs2076280 | Additive models | TT vs. CT vs. CC | 1.172 (0.866–1.587) | 0.305 | 1.011 (0.680–1.501) | 0.959 | 1.381 (0.865–2.024) | 0.176 |
|       | Dominant model       | CT+TT vs. CC       | 1.120 (0.833–1.506) | 0.454 | 1.003 (0.680–1.479) | 0.988 | 1.257 (0.795–1.990) | 0.328 |
|       | Recessive model      | TT vs. CT+CC       | 0.532 (0.188–1.511) | 0.236 | 0.870 (0.203–3.724) | 0.851 | 0.358 (0.074–1.735) | 0.202 |
|       | Allele comparison    | T vs. C            | 1.092 (0.827–1.441) | 0.535 | 1.005 (0.697–1.540) | 0.979 | 1.205 (0.780–1.881) | 0.401 |
| rs2282715 | Additive models | AA vs. GA vs. GG | 0.948 (0.686–1.308) | 0.744 | 1.040 (0.679–1.591) | 0.858 | 0.865 (0.525–1.426) | 0.57 |
|       | Dominant model       | GA+AA vs. GG       | 0.984 (0.728–1.330) | 0.915 | 1.147 (0.770–1.709) | 0.5   | 0.822 (0.515–1.312) | 0.411 |
|       | Recessive model      | AA vs. GA+GG       | 1.102 (0.797–1.522) | 0.558 | 1.369 (0.902–2.075) | 0.14  | 0.808 (0.482–1.354) | 0.418 |
|       | Allele comparison    | A vs. G            | 1.039 (0.847–1.275) | 0.714 | 1.161 (0.892–1.510) | 0.268 | 0.888 (0.639–1.233) | 0.477 |

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.

<sup>a</sup>OR adjusted for gender, age, BMI, TCHO, HDL-C, LDL-C, TG, glucose, and Hcy.

<sup>b</sup>OR adjusted for age, BMI, TCHO, HDL-C, LDL-C, TG, glucose, and Hcy.

<sup>c</sup>OR adjusted for age, BMI, TCHO, HDL-C, TG, glucose, and Hcy.

<sup>*p < .05.</sup>
However, the subjects were adequately matched for age and gender between groups. As we can see, the mean age was comparable in the two sets. And most patients have passed the high-risk age of EH. Second, it is noticeable that rs2236847 was also related to EH in females under addictive model, but no positive result was found in other genetic models for this SNP. Besides, the positive haplotype of rs2076283-rs2236847 identified in current study was originated from two negative SNPs when working alone. So results achieved in this study need further exploration. Third, only common tag SNPs with the MAF over 10% were analyzed here, other functional SNPs with lower frequency are still worthy of study.

Finally in a word, the current study suggested that several SNPs and related haplotypes on ECE1 gene might be associated with the susceptibility of EH, which providing evidences to the early prevention, risk assessment and individualized therapy of EH to some extent. Due to the mentioned limitations, further researches are needed to confirm the above deduction.

### 5 | DATA AVAILABLE STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

---

**FIGURE 1** Linkage disequilibrium (LD) blocks defined by the Haplovview program based on the solid spine of LD method. A. represents LD results of $D’$; B. represents LD results of $r^2$.

**TABLE 4** Haplotype analysis of ECE1 polymorphisms in case and control groups

| Block | SNP1        | SNP2        | Haplotype | Frequency |
|-------|-------------|-------------|-----------|-----------|
|       | rs11590928  | rs9426748   | T-A       | 0.254     |
|       |             |             | C-A       | 0.111     |
|       |             |             | C-C       | 0.626     |
| 1     |             |             | G-T       | 0.446     |
|       | rs212515    | rs2282715   | A-A       | 0.477     |
|       |             |             | C-G       | 0.33      |
|       |             |             | A-G       | 0.192     |
| 2     |             |             | G-T       | 0.463     |
|       | rs2076283   | rs2236847   | T-A       | 0.033     |
|       |             |             | C-C       | 0.519     |

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.

*ORs and $p$-values for the haplotype-based association analysis with a specific haplotype compared with the others.

*ORs and $p$-values for the haplotype-based logistic regression analysis after adjusting for gender, age, BMI, TCHO, HDL-C, LDL-C, TG, glucose, and Hcy.

* $p < .05$. 

---

DATA AVAILABLE STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.
ACKNOWLEDGMENTS
We are very grateful and thank all the participants in this study. H.W. and J.L.L. performed most of data acquisition, analysis and manuscript drafting. K.L., Y.L., and J.W. helped with database setup and data collection. SJ.W contributed to the funding acquisition. SJ.W and ZG.W made manuscript conception design and revision. All the authors read and approved the final manuscript. This work was financially supported by Beijing Natural Science Foundation (7120001) and Beijing Natural Science Foundation (7102045) (http://www.bjnsf.org/) from the Ministry of Science and Technology in the People’s Republic of China.

CONFLICT OF INTEREST
The authors report no conflict of interest.

ORCID
Hao Wang https://orcid.org/0000-0001-5694-1203
Shaojun Wen https://orcid.org/0000-0001-5839-9518

REFERENCES
Banno, M., Hanada, H., Kamide, K., Kokubu, Y., Kada, A., Yang, J., … Miyata, T. (2007). Association of genetic polymorphisms of endothelin-converting enzyme-1 gene with hypertension in a Japanese population and rare missense mutation in preproendothelin-1 in Japanese hypertensives. *Hypertension Research*, 30(6), 513–520. https://doi.org/10.1291/hypres.30.513
Dhaun, N., & Webb, D. J. (2019). Endothelins in cardiovascular biology and therapeutics. *Nature Reviews Cardiology*, 16(8), 491–502. https://doi.org/10.1038/s41569-019-0176-3
Dong, S.-S., Hu, W.-X., Yang, T.-L., Chen, X.-F., Yan, H., Chen, X.-D., … Guo, Y. (2017). SNP-SNP interactions between WNT4 and WNT5A were associated with obesity related traits in Han Chinese Population. *Scientific Reports*, 7, 43939. https://doi.org/10.1038/srep43939
Dubey, R. K., Jackson, E. K., Keller, P. J., Imthurn, B., & Rosselli, M. (2001). Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. *Hypertension*, 37(2 Pt 2), 640–644. https://doi.org/10.1161/01.hyp.37.2.640
Funalot, B., Bourbon, D., Brousseau, T., Poirier, O., Barr, C., Cambien, F., … Ducimetière, P. (2004). Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: The EVA study. *Journal of Hypertension*, 22(4), 739–743. https://doi.org/10.1097/00002438-200404000-00016
Funke-Kaiser, H., Reichenberger, F., Kopke, K., Herrmann, S. M., Pfeifer, J., Orzechowski, H. D., … Brand, E. (2003). Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. *Human Molecular Genetics*, 12(4), 423–433. https://doi.org/10.1093/hmg/ddg040
Gao, Y., Chen, G., Tian, H., Lin, L., Lu, J., Weng, J., … Yang, W.; The China National Diabetes and Metabolic Disorders Study Group. (2013). Prevalence of hypertension in China: A Cross-Sectional Study. *PLoS ONE*, 8(6), e65938. https://doi.org/10.1371/journal.pone.0065938
Ge, D., Huang, J., He, J., Li, B., Duan, X., Chen, R., & Gu, D. (2005). beta2-Adrenergic receptor gene variations associated with stage-2 hypertension in northern Han Chinese. *Annals of Human Genetics*, 69( Pt 1), 36–44. https://doi.org/10.1046/j.1529-8817.2003.00093.x
Gohar, E. Y., & Pollock, D. M. (2018). Sex-specific contributions of endothelin to hypertension. *Current Hypertension Reports*, 20(7), 58. https://doi.org/10.1007/s11906-018-0856-0
Grossi, V., Forte, G., Sanse, P., Pelerico, A., Tezli, T., Lepore Signorile, M., … Simone, C. (2018). The longevity SNP rs2802292 uncovered: HSF1 activates stress-dependent expression of FOXO3 through an intronic enhancer. *Nucleic Acids Research*, 46(11), 5587–5600. https://doi.org/10.1093/nar/gky331
Gu, D., Su, S., Ge, D., Chen, S., Huang, J., Li, B., … Qiang, B. (2006). Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. *Hypertension*, 47(6), 1147–1154. https://doi.org/10.1161/01.hyp.0000219041.66702.45
Iemitsu, M., Maeda, S., Otsuki, T., Sugawara, J., Tanabe, T., Jesmin, S., … Matsuda, M. (2006). Polymorphism in endothelin-related genes limits exercise-induced decreases in arterial stiffness in older subjects. *Hypertension*, 47(5), 928–936. https://doi.org/10.1161/01.hyp.0000217520.44176.73
Intapad, S., Ojeda, N. B., Varney, E., Royals, T. P., & Alexander, B. T. (2015). Sex-specific effect of endothelin in the blood pressure response to acute angiotensin II in growth-restricted rats. *Hypertension*, 66(6), 1260–1266. https://doi.org/10.1161/hypertensionaha.115.06257
Jo, B. S., & Choi, S. S. (2015). Introns: The functional benefits of introns in genomes. *Genomics Inform*, 13(4), 112–118. https://doi.org/10.5808/gi.2015.13.4.112
Lazar, A., Zimmermann, T., Koch, W., Gründemann, D., Schömig, A., Kastrati, A., & Schömig, E. (2006). Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. *Clinical and Experimental Hypertension*, 28(7), 645–653. https://doi.org/10.1080/10641960600946411
Le Hir, H., Nott, A., & Moore, M. J. (2003). How introns influence and enhance eukaryotic gene expression. *Trends in Biochemical Sciences*, 28(4), 215–220. https://doi.org/10.1016/s0968-0004(03)00052-5
Levy, N., Gordin, M., Mamluk, R., Yanagisawa, M., Smith, M. F., Hampton, J. H., & Meidan, R. (2001). Distinct cellular localization and regulation of endothelin-1 and endothelin-converting enzyme-1 expression in the bovine corpus luteum: Implications for luteolysis. *Endocrinology*, 142(12), 5254–5260. https://doi.org/10.1210/endo.142.12.8550
Li, H., Li, Q., Zhang, Y., Liu, W., Gu, B. O., Narumi, T., … Cai, H. (2015). Novel treatment of hypertension by specifically targeting transcription factor E2F for restoration of endothelial dihydrofolate reductase and eNOS function under oxidative stress. *Hypertension*, 71(1), 179–189. https://doi.org/10.1161/HYPERTENSIONAHA.118.11643
Li, Q., Liu, X., Zhang, X., Zhang, H., Wang, J., & He, Z. (2017). Association of endothelin converting enzyme-1 polymorphisms with essential hypertension. *Progress of Anatomical Sciences*, 225–227. https://doi.org/10.16695/j.cnki.1006-2947.2017.03.001
Luscher, T. F., & Barton, M. (2000). Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs. *Circulation*, 102(19), 2434–2440. https://doi.org/10.1161/01.cir.102.19.2434
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., … Zannad, F. (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology
WANG et Al. (ESC). Journal of Hypertension, 31(7), 1281–1357. https://doi.org/10.1097/01.jht.0000431740.32696.cc

Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., … He, J. (2016). Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation, 134(6), 441–450. https://doi.org/10.1161/circulationaha.115.018912

Minamino, T., Kurihara, H., Takahashi, M., Shimada, K., Maemura, K., Oda, H., … Yazaki, Y. (1997). Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation, 95(1), 221–230. https://doi.org/10.1161/01. cir.95.1.221

Polderman, K. H., Stehouwer, C. D., van Kamp, G. J., Dekker, G. A., Verheugt, F. W., & Gooren, L. J. (1993). Influence of sex hormones on plasma endothelin levels. Annals of Internal Medicine, 118(6), 429–432. https://doi.org/10.7326/0003-4819-118-6-199303150-00006

Prisco, S. Z., Prokop, J. W., Sarkis, A. B., Yeo, N. C., Hoffman, M. J., Hansen, C. C., … Lazar, J. (2014). Refined mapping of a hypertension susceptibility locus on rat chromosome 12. Hypertension, 64(4), 883–890. https://doi.org/10.1161/HYPERTENSIONAHA.114.03550

Sakharkar, M. K., Chow, V. T., & Kangueane, P. (2004). Distributions of exons and introns in the human genome. In Silico Biology, 4(4), 387–393.

Shirai, N., Naruko, T., Ohsawa, M., Ikura, Y., Sugaya, Y., Hirayama, M., … Ueda, M. (2006). Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans. Journal of Hypertension, 24(4), 711–721. https://doi.org/10.1097/01.jht.0000217854.97369.8c

Song, J. J., Ma, Z., Wang, J., Chen, L. X., & Zhong, J. C. (2019). Gender differences in hypertension. Journal of Cardiovascular Translational Research, https://doi.org/10.1007/s12265-019-09888-z

Stamler, R., Stamler, J., Riedlinger, W. F., Algera, G., & Roberts, R. H. (1979). Family (parental) history and prevalence of hypertension. Results of a nationwide screening program. JAMA, 241(1), 43–46. https://doi.org/10.1001/jama.1979.03290270033016

How to cite this article: Wang H, Liu J, Liu K, et al. Association of ECE1 gene polymorphisms and essential hypertension risk in the Northern Han Chinese: A case–control study. Mol Genet Genomic Med. 2020;8:e1188. https://doi.org/10.1002/mgg3.1188